Krystal Biotech, Inc. (KRYS) stock
KRYSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 11/3042% above fair value
$305.23−0.45 (-0.15%)
Close on Nov 13, 2026Market cap $9.03BP/E 41.4Yield –
Krystal Biotech operating margin
Operating margin is operating income as a percentage of revenue.
Krystal Biotech's operating margin for the twelve months ending Sep 30, 2026 was 48.4%. For fiscal 2025 it was 41.5%, against 22.6% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 41.5% | +18.8 |
| FY2024 | Dec 31, 2024 | 22.6% | +238.8 |
| FY2023 | Dec 31, 2023 | -216.2% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 55.9% | +13.6 |
| Q2 FY2026 | Jun 30, 2026 | 49.0% | +8.0 |
| Q1 FY2026 | Mar 31, 2026 | 46.1% | +5.0 |
| Q4 FY2025 | Dec 31, 2025 | 41.3% | −4.1 |
| Q3 FY2025 | Sep 30, 2025 | 42.3% | +15.5 |
| Q2 FY2025 | Jun 30, 2025 | 41.0% | +28.8 |
| Q1 FY2025 | Mar 31, 2025 | 41.1% | +55.9 |
| Q4 FY2024 | Dec 31, 2024 | 45.4% | +37.7 |
| Q3 FY2024 | Sep 30, 2024 | 26.8% | +330.6 |
| Q2 FY2024 | Jun 30, 2024 | 12.2% | – |
| Q1 FY2024 | Mar 31, 2024 | -14.8% | – |
| Q4 FY2023 | Dec 31, 2023 | 7.7% | – |
| Q3 FY2023 | Sep 30, 2023 | -303.8% | – |
See a number that looks wrong?